Choi Han Seok, Kim Sunmi, Kim Min Jung, Kim Myung-Sunny, Kim Juewon, Park Chan-Woong, Seo Daebang, Shin Song Seok, Oh Sang Woo
Division of Endocrinology and Metabolism, Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Gyeonggi, Republic of Korea.
Research and Development Center, Amorepacific Corporation, Yongin, Gyeonggi, Republic of Korea.
J Ginseng Res. 2018 Jan;42(1):90-97. doi: 10.1016/j.jgr.2017.01.003. Epub 2017 Jan 10.
Antihyperglycemic effects of berry have never been explored in humans. The aims of this study were to assess the efficacy and safety of a 12-wk treatment with ginseng berry extract in participants with a fasting glucose level between 100 mg/dL and 140 mg/dL.
This study was a 12-wk, randomized, double-blind, placebo-controlled clinical trial. A total of 72 participants were randomly allocated to two groups of either ginseng berry extract or placebo, and 63 participants completed the study. The parameters related to glucose metabolism were assessed.
Although the present study failed to show significant antihyperglycemic effects of ginseng berry extract on the parameters related to blood glucose and lipid metabolism in the total study population, it demonstrated that ginseng berry extract could significantly decrease serum concentration of fasting glucose by 3.7% ( = 0.035), postprandial glucose at 60 min during 75 g oral glucose tolerance test by 10.7% ( = 0.006), and the area under the curve for glucose by 7.7% ( = 0.024) in those with fasting glucose level of 110 mg/dL or higher, while the placebo group did not exhibit a statistically significant decrease. Safety profiles were not different between the two groups.
The present study suggests that ginseng berry extract has the potential to improve glucose metabolism in human, especially in those with fasting glucose level of 110 mg/dL or higher. For a more meaningful benefit, further research in people with higher blood glucose levels is required.
浆果的降血糖作用从未在人体中进行过研究。本研究的目的是评估人参果提取物对空腹血糖水平在100mg/dL至140mg/dL之间的参与者进行12周治疗的疗效和安全性。
本研究是一项为期12周的随机、双盲、安慰剂对照临床试验。总共72名参与者被随机分配到人参果提取物组或安慰剂组,63名参与者完成了研究。评估了与葡萄糖代谢相关的参数。
尽管本研究未能在整个研究人群中显示人参果提取物对与血糖和脂质代谢相关参数有显著的降血糖作用,但结果表明,人参果提取物可使空腹血糖水平在110mg/dL或更高的参与者的空腹血糖血清浓度显著降低3.7%(P=0.035),在75g口服葡萄糖耐量试验中60分钟时的餐后血糖降低10.7%(P=0.006),葡萄糖曲线下面积降低7.7%(P=0.024),而安慰剂组未显示出统计学上的显著降低。两组的安全性概况无差异。
本研究表明,人参果提取物有改善人体葡萄糖代谢的潜力,尤其是空腹血糖水平在110mg/dL或更高的人群。为获得更有意义的益处,需要对血糖水平更高的人群进行进一步研究。